Efficacy and safety of Shen-Yuan-Dan capsules for peri-procedural myocardial injury following percutaneous coronary intervention: study protocol for a randomized, double-blind, placebo-controlled trial

Li, Xiang; Lai, Xiao-Lei; Fei, Yutong; Shang, Juju; Zhou, Qi; Sun, Xuguo; Xing, Wenlong; Jia, Si-Han; Liu, Hongxu

doi:10.21037/atm.2018.09.44

Cited by 3 publications

(5 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinically, SYDC, as one of our hospital preparations, has been used for clinical treatment of unstable angina pectoris for more than 30 years with favorable therapeutic effects (Li et al, 2019). Studies have shown that SYDC improved the clinical symptoms in patients with unstable angina (Li et al, 2019) and exerted myocardial protective effect through endothelial protection, antioxidative stress, and other mechanisms (Liu et al, 2013). Because zebrafish are sensitive to the effect of drugs, some adverse reactions, such as yolk sac blackening and heart rate slowing, may occur.…”

Section: Discussionmentioning

confidence: 99%

“…Clinically, SYDC, as one of our hospital preparations, has been used for clinical treatment of unstable angina pectoris for more than 30 years with favorable therapeutic effects ( Li et al, 2019 ). SYDC is a TCM compound containing eight traditional herbs: Hirudo , Astragali Radix , Codonopsis Radix , Pheretima , Eupolyphaga Seu Steleophaga , Corydalis Rhizoma , Salviae Miltiorrhizae Radix et Rhizoma , and Scrophulariae Radix .…”

Section: Discussionmentioning

confidence: 99%

“…SYDC is a TCM compound containing eight traditional herbs: Hirudo , Astragali Radix , Codonopsis Radix , Pheretima , Eupolyphaga Seu Steleophaga , Corydalis Rhizoma , Salviae Miltiorrhizae Radix et Rhizoma , and Scrophulariae Radix . Studies have shown that SYDC improved the clinical symptoms in patients with unstable angina ( Li et al, 2019 ) and exerted myocardial protective effect through endothelial protection, antioxidative stress, and other mechanisms ( Liu et al, 2013 ). Because zebrafish are sensitive to the effect of drugs, some adverse reactions, such as yolk sac blackening and heart rate slowing, may occur.…”

Section: Discussionmentioning

confidence: 99%

“…Shen-Yuan-Dan capsule (SYDC), a hospital preparation of traditional Chinese herbal medicine, has been used for clinical treatment of unstable angina pectoris for more than 30 years with favorable effect ( Li et al, 2019 ). Previous studies have shown that it can inhibit oxygen-free radicals in ischemic myocardium, improve myocardial tissue's antioxidant ability, and inhibit inflammatory reaction in vivo ( Liu et al, 2013 ; Zhou et al, 2017 ).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Shen-Yuan-Dan Capsule Attenuates Verapamil-Induced Zebrafish Heart Failure and Exerts Antiapoptotic and Anti-Inflammatory Effects via Reactive Oxygen Species–Induced NF-κB Pathway

Liu

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Heart failure (HF) is the end stage of ischemic cardiovascular diseases; nonetheless, safe and effective therapeutic agents for HF are still lacking, and their discovery remains challenging. Our previous studies demonstrated that Shen-Yuan-Dan Capsule (SYDC), a hospital preparation of traditional Chinese herbal, effectively protected ischemic injury in cardiovascular diseases. However, its therapeutic effects and possible mechanisms on HF remain unclear.Methods: A zebrafish HF model treated with verapamil was developed to assess the therapeutic effect of SYDC on HF zebrafish. Zebrafish were administered with SYDC and digoxin (positive control) by direct soaking. After drug treatment, zebrafish were randomly assigned to the visual observation and image acquisition using a Zebralab Blood Flow System. The reactive oxygen species (ROS), MDA, and SOD levels were determined by fluorescence signal detection, TBA, and WST-8 methods. RT-PCR determined the mRNA expressions of Caspase-3, Caspase-1, Bcl-2, Bax, IL-1β, NF-κB, and TNF-α.Results: SYDC significantly inhibited the levels of heart dilatation and venous congestion and markedly increased the levels of cardiac output, blood flow dynamics, and heart rates in HF zebrafish (p < 0.05, p < 0.01, and p < 0.001). Moreover, SYDC also significantly decreased the levels of MDA and ROS and increased the level of SOD in HF zebrafish. The RT-PCR results revealed that SYDC decreased the expression of Caspase-1, Caspase-3, Bax, IL-1β, NF-κB, and TNF-α but increased the expression of Bcl-2 in HF zebrafish (p < 0.05, p < 0.01, and p < 0.001).Conclusions: SYDC improved the heart function in verapamil-induced HF zebrafish and alleviated inflammation and apoptosis by inhibiting the ROS-mediated NF-κB pathway.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Clinically, SYDC, as one of our hospital preparations, has been used for clinical treatment of unstable angina pectoris for more than 30 years with favorable therapeutic effects ( Li et al, 2019 ). SYDC is a TCM compound containing eight traditional herbs: Hirudo , Astragali Radix , Codonopsis Radix , Pheretima , Eupolyphaga Seu Steleophaga , Corydalis Rhizoma , Salviae Miltiorrhizae Radix et Rhizoma , and Scrophulariae Radix .…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Shen-Yuan-Dan Capsule Attenuates Verapamil-Induced Zebrafish Heart Failure and Exerts Antiapoptotic and Anti-Inflammatory Effects via Reactive Oxygen Species–Induced NF-κB Pathway

Liu

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…e study related to ARMYDA showed that preoperative loading of atorvastatin calcium could reduce the occurrence of PMI [6][7][8], but this result has not been effectively confirmed in the Asian population [9]. erefore, investigating drugs that can effectively prevent PMI remains a hot spot in medical research [10].…”

Section: Introductionmentioning

confidence: 99%

Effects of Shen-Yuan-Dan on Periprocedural Myocardial Injury and the Number of Peripheral Blood Endothelial Progenitor Cells in Patients with Unstable Angina Pectoris Undergoing Elective Percutaneous Coronary Intervention

Zhang

Xing

Liu

et al. 2022

Evidence-Based Complementary and Alternative Medicine

Self Cite

View full text Add to dashboard Cite

Objectives. We aimed to investigate the effects of Shen-Yuan-Dan (SYD), a Chinese medicine preparation, on periprocedural myocardial injury (PMI) and the number of peripheral blood endothelial progenitor cells (EPCs) in patients with unstable angina pectoris (UA) who underwent elective percutaneous coronary intervention (PCI). Methods. Patients were randomly divided into the experimental (group A) and control (group B) groups through the random number table method. In group A, patients concurrently received the conventional western treatment and SYD orally (4 capsules/time, 3 times/d, from 3 d before surgery to 7 d after surgery). In group B, patients received conventional Western medicine treatment. Both groups underwent coronary angiography, and patients undergoing PCI were eventually included in the study. The following patient data were collected: incidence of PMI, serum CK-MB content before PCI, 4 h, 24 h, and 7 d after PCI, number of CD45dim/-CD34+CD309+ peripheral venous EPCs, and number of CD184 coexpressed EPCs. The incidence of adverse reactions and 30-day major adverse cardiovascular events (MACEs) were also recorded. Results. Sixty-two patients were finally included in this study, with 32 and 30 in groups A and B, respectively. In group A, the number of peripheral blood EPCs and the number of CD184 coexpressed EPCs at 1 h before surgery were higher than those at 3 d before surgery (37.24 ± 25.20 vs. 22.78 ± 9.60/ml; P < 0.001 and 23.38 ± 15.30 vs. 13.54 ± 8.08/ml; P < 0.001 , resp.). The number of peripheral blood EPCs and number of CD184 coexpressed EPCs at 4 h after surgery were lower than those at 1 h before surgery (25.30 ± 11.90 vs. 37.24 ± 25.20/ml; P = 0.019 and 15.38 ± 8.78 vs. 23.38 ± 15.30/ml; P = 0.013 , resp.), but there was no difference at 24 h and at 7 d after surgery in comparison with that at 1 h before surgery ( P > 0.05 ). In group B, compared with that at 1 h before surgery, there existed a decline in the number of EPCs in peripheral blood and the number of CD184 coexpressed EPCs at 4 h after surgery, but without a statistical difference ( P > 0.05 ). Comparing both groups, it was found that the incidence of PMI in group A was lower (6.25% vs. 26.67%; P = 0.04 ), and the serum CK-MB content at 4 and 24 h after surgery was also lower than that in group B (17.33 ± 5.83 vs. 20.38 ± 4.32 U/l; P = 0.048 and 15.79 ± 5.32 vs. 19.10 ± 4.93 U/l; P = 0.030 , resp.). The number of EPCs in peripheral blood and the number of CD184 coexpressed EPCs in group A were higher than those in group B at 1 h before surgery (37.24 ± 25.20 vs. 22.36 ± 12.26/ml; P = 0.034 and 23.38 ± 15.30 vs. 13.12 ± 14.62/ml; P = 0.013 , resp.). In addition, there were no obvious adverse reactions and no 30-day MACEs in both groups during the trial. Conclusion. SYD can reduce PMI and promote the mobilization of EPCs in the perioperative period of elective PCI in patients with UA.

show abstract

A randomized, placebo-controlled, double-blind trial to evaluate efficacy and safety of Shen-Yuan-Dan capsules, a traditional Chinese medicine, for treatment of peri-procedure myocardial injury following percutaneous coronary intervention

Zhang

Liu

et al. 2022

Complementary Therapies in Medicine

View full text Add to dashboard Cite

Efficacy and safety of Shen-Yuan-Dan capsules for peri-procedural myocardial injury following percutaneous coronary intervention: study protocol for a randomized, double-blind, placebo-controlled trial

Cited by 3 publications

References 13 publications

Shen-Yuan-Dan Capsule Attenuates Verapamil-Induced Zebrafish Heart Failure and Exerts Antiapoptotic and Anti-Inflammatory Effects via Reactive Oxygen Species–Induced NF-κB Pathway

Shen-Yuan-Dan Capsule Attenuates Verapamil-Induced Zebrafish Heart Failure and Exerts Antiapoptotic and Anti-Inflammatory Effects via Reactive Oxygen Species–Induced NF-κB Pathway

Effects of Shen-Yuan-Dan on Periprocedural Myocardial Injury and the Number of Peripheral Blood Endothelial Progenitor Cells in Patients with Unstable Angina Pectoris Undergoing Elective Percutaneous Coronary Intervention

A randomized, placebo-controlled, double-blind trial to evaluate efficacy and safety of Shen-Yuan-Dan capsules, a traditional Chinese medicine, for treatment of peri-procedure myocardial injury following percutaneous coronary intervention

Contact Info

Product

Resources

About